米食品医薬品局(FDA)が、ペムブロリズマブおよびアテゾリズマブの単剤投与について、局所進行性/転移性尿路上皮がんに対する使用を厳格化【FDA】

FDA Alerts Health Care Professionals and Oncology Clinical Investigators about an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1

コメント

Leave a comment

Your email address will not be published.


*